课题基金 / 基金详情

Task X19: GMP Manufacturing for a Malaria Vaccine

Task X19: GMP Manufacturing for a Malaria Vaccine
任务 X19：疟疾疫苗的 GMP 生产
批准号：
10925113
负责人：
JAMES RICHARDSON
金额：
$2.81万
依托单位：
ADVANCED BIOSCIENCE LABORATORIES, INC.
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
项目状态：
已结题
起止时间：
2016-04-22 至 2022-07-19
来源：
https://reporter.nih.gov/project-details/10925113
关键词：
Biological ProductsBioterrorismClinical ResearchCommunicable DiseasesContractsCyclic GMPDevelopmentDevelopment PlansEmerging Communicable DiseasesMalaria VaccinesPhasePlasmodium falciparum vaccineServicesToxicologyUnited States Food and Drug AdministrationVaccinesdrug resistant pathogenmanufacturenovel vaccinesproduct development

项目摘要

项目成果

JAMES RICHARDSON的其他基金

相似基金

相关文献

中文摘要
翻译
传染病疫苗和其他生物制品的制造和表征服务(MCS)合同提供各种产品开发服务，包括产品开发规划和可行性评估；I/II期临床研究的产品开发和符合cGMP标准的制造；毒理学研究；技术和设施审计；以及适用于提交美国食品和药物管理局(FDA)的监管支持。这些服务将促进开发和引入新的疫苗和生物制品，以应对生物恐怖主义、抗药性病原体以及新出现和重新出现的传染病的潜在病原体。该合同还规定了挑战材料的制造。
英文摘要
The Manufacture and Characterization Services (MCS) for Vaccines and Other Biologics for Infectious Diseases contract provides a variety of product development services spanning product development planning and feasibility assessments; product development and cGMP compliant manufacture for Phase I/II clinical studies; toxicology studies; technical and facility audits; and regulatory support appropriate for submission to the U.S. Food and Drug Administration (FDA). These services will facilitate the development and introduction of new vaccines and biologics against potential agents of bioterrorism, drug-resistant pathogens, and emerging and re-emerging infectious diseases. This contract also provides for manufacture of challenge material.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Task X5: Master Cell Bank for Chlamydia Trachoma Vaccine
Task X6: Development of Candida Vaccines
Task X18: Process Development and Early Reagent Manufacturing for Vaccines and Other Biologics
Task X7: Malaria Vaccines Stability Study
海外基金